Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Sales | 376,267 | 324,656 | 296,493 | 121,581 | 84,209 |
| Cost of Goods | 70,285 | 65,909 | 52,509 | 18,359 | 8,740 |
| Gross Profit | 305,982 | 258,747 | 243,984 | 103,222 | 75,469 |
| Operating Expenses | 305,723 | 243,229 | 204,737 | 160,869 | 119,633 |
| Operating Income | 544 | 16,427 | 39,756 | -57,288 | -43,424 |
| Interest Expense | 10,818 | 14,090 | 16,394 | 14,243 | 13,411 |
| Other Income | -11,216 | -1,771 | 10,062 | 56,457 | 28,376 |
| Pre-tax Income | -21,490 | 566 | 33,424 | -15,074 | -28,459 |
| Income Tax | -227,309 | 1,054 | 2,593 | 729 | 74 |
| Net Income Continuous | 205,819 | -488 | 30,831 | -15,803 | -28,533 |
| Net Income | $205,819 | $-488 | $30,831 | $-15,803 | $-28,533 |
| EPS Basic Total Ops | 2.00 | 0.00 | 0.31 | -0.16 | -0.34 |
| EPS Basic Continuous Ops | 2.00 | 0.00 | 0.31 | -0.16 | -0.34 |
| EPS Diluted Total Ops | 1.73 | 0.00 | 0.29 | -0.16 | -0.34 |
| EPS Diluted Continuous Ops | 1.64 | 0.00 | 0.30 | -0.16 | -0.34 |
| EBITDA(a) | $32,734 | $38,845 | $50,886 | $-56,087 | $-33,642 |